secwatch.observer — SEC 8-K summary
======================================

Issuer:     Passage BIO, Inc. (PASG)
CIK:        0001787297
Form:       8-K
Filed at:   2024-03-04T23:59:59+00:00
Accession:  0001558370-24-002309
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Passage Bio reports FY2023 net loss of $102.1M, appoints Kathleen Borthwick as CFO; cash runway into Q4 2025
--------------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities $114.3M as of Dec 31, 2023; cash runway expected into Q4 2025.
- FY2023 net loss $102.1M ($1.86 per share); FY2022 net loss $136.1M ($2.50 per share).
- Kathleen Borthwick appointed as permanent CFO effective March 1, 2024; base salary $422,240 plus options.
- PBFT02 for FTD-GRN shows CSF progranulin elevated to supraphysiologic levels; cohort 1 dosing completion expected 1H 2024.
- Company evaluating PBFT02 for FTD-C9orf72, ALS, and Alzheimer's; seeking regulatory feedback in 2H 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787297/000155837024002309/0001558370-24-002309-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787297/000155837024002309/pasg-20240304x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-002309

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer